Addictive disorders: Samuel C. Johnson Genomics of Addiction Program

The Samuel C. Johnson Genomics of Addiction program brings together a multidisciplinary, integrated group of clinicians and scientists to better understand how genetic vulnerability is related to the onset and treatment of alcohol, drugs and other addictions. The group concentrates on developing individualized molecular strategies for alcoholism treatment, with the primary focus on studying the pharmacogenomics of anti-craving medications.

The research team completed a P20 developmental grant from the National Institute on Alcohol Abuse and Alcoholism. The focus included development of systematic pharmacogenomics and imaging of pharmacological treatments for alcoholism, with an emphasis on acamprosate, a Food and Drug Administration-approved medication for treating alcoholism.

Currently, investigators are involved in addiction, neuroscience, genetics and psychiatry research. With future support from the National Institutes of Health and benefactors, the team plans to expand studies into treatments for alcoholism that is co-occurring with depression. Funding for a comprehensive center for the study of alcoholism and depression has been proposed to the NIAAA.

Investigators

Grants

Investigator & Role Grant Title Funding Source Duration
Marin Veldic, M.D., principal investigator Epigenetic DNA Methylation in Bipolar Disorders Mayo Clinic Center for Individualized Medicine award 08/2012-07/2015
Doo-Sup Choi, Ph.D., principal investigator Alcohol and Adenosine-Mediated Glutamate Signaling in Neuronglial Interaction National Institute of Alcohol Abuse and Alcoholism 09/2009-08/2014
Osama A. Abulseoud, M.D., principal investigator Preclinical Glutamate Modulation Through Deep Brain Stimulation as a Novel Target for Alcohol Addiction Mayo Clinic Center for Translational Science Activities KL2 Mentored Career Development award 07/2011-06/2014